News
News
- Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum
01/02/2020 / 22:15 - GlobeNewswire - Novan Announces Planned Chief Executive Officer Transition
12/18/2019 / 14:00 - GlobeNewswire - Novan Further Expands its Proprietary Nitric Oxide Platform
10/18/2019 / 14:30 - GlobeNewswire - Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology
10/08/2019 / 14:30 - GlobeNewswire - Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/11/2019 / 22:05 - GlobeNewswire - Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
09/05/2019 / 12:30 - GlobeNewswire - Novan to Participate in H.C. Wainwright 21st Annual Global Investment Conference
09/03/2019 / 15:00 - GlobeNewswire - Novan Advances Women’s Health Business Unit with Non-Dilutive Funding
08/14/2019 / 14:15 - GlobeNewswire - Novan Takes Steps to Reduce Real Estate Footprint
08/13/2019 / 22:15 - GlobeNewswire - Novan’s Phase 3 Molluscum Pivotal Program Completes Enrollment
08/13/2019 / 14:15 - GlobeNewswire
Real-time